SEARCH

SEARCH BY CITATION

References

  • 1
    Cattaneo M. Congenital disorders of platelet secretion. In: GreseleP, PageC, FusterV, VermylenJ, eds. Platelets in Thrombotic and Non-Thrombotic Disorders. Cambridge: Cambridge University Press. 2002: 65573.
  • 2
    Clemetson KJ, Clemetson JM. Platelet adhesive protein defect disorders. In: GreseleP, PageC, FusterV, VermylenJ, eds. Platelets in Thrombotic and Non-Thrombotic Disorders. Cambridge: Cambridge University Press. 2002: 63954.
  • 3
    Rao AK. Congenital platelet signal transduction defects. In: GreseleP, PageC, FusterV, VermylenJ, eds. Platelets in Thrombotic and Non-Thrombotic Disorders. Cambridge: Cambridge University Press. 2002: 67488.
  • 4
    Clemetson KJ, Clemetson JM. Congenital disorders of platelet function. Haematologica (Supplement 85: The Platelet ADP Receptors). 2000, 3745.
  • 5
    Balduini CL, Cattaneo M, Fabris F, Gresele P, Iolascon A, Savoia A. Inherited thrombocytopenias: proposal of a diagnostic algorythm by the Italia ‘Gruppo di Studio delle Piastrine’. Haematologica 2003; 88: 58292.
  • 6
    Balduini CL, Iolascon A, Savoia A. Inherited thrombocytopenias: from genes to therapy. Haematologica 2002; 87: 86080.
  • 7
    Van Geet C, Freson K, Devos R, Vermylen J. Hereditary thrombocytopenias. In: Gresele, P, Page, C, Fuster, V, Vermylen, J, eds. Platelets in Thrombotic and Non-Thrombotic Disorders. Cambridge: Cambridge University Press. 2002: 51527.
  • 8
    De Marco L, Mazzucato M, Masotti A, Ruggeri ZM. Localization and characterization of an alpha-thrombin-binding site on platelet glycoprotein Ib alpha. J Biol Chem 1994; 269: 647884.
  • 9
    Jamieson GA, Okumura T. Reduced thrombin binding and aggregation in Bernard–Soulier platelets. J Clin Invest 1978; 61: 8614.
  • 10
    De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem 2001; 276: 46928.
  • 11
    Dormann D, Clemetson KJ, Kehrel BE. The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood 2000; 96: 246978.
  • 12
    Ruggeri ZM. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol 2001; 14: 25779.
  • 13
    Russell SD, Roth GJ. Pseudo-von Willebrand disease: a mutation in the platelet glycoprotein Ib alpha gene associated with a hyperactive surface receptor. Blood 1993; 81: 178791.
  • 14
    Miller JL, Cunningham D, Lyle VA, Finch CN. Mutation in the gene encoding the alpha chain of platelet glycoprotein Ib in platelet-type von Willebrand disease. Proc Natl Acad Sci USA 1991; 88: 47615.
  • 15
    Dong J, Schade AJ, Romo GM, Andrews RK, Gao S, McIntire LV, Lopez JA. Novel gain-of-function mutations of platelet glycoprotein IBalpha by valine mutagenesis in the Cys209-Cys248 disulfide loop. Functional analysis under statis and dynamic conditions. J Biol Chem 2000; 275: 2766370.
  • 16
    Bolin RB, Okumra T, Jamieson GA. New polymorphism of platelet membrane glycoproteins. Nature 1977; 269: 6970.
  • 17
    Meyer M, Schellenberg I. Platelet membrane glycoprotein Ib: genetic polymorphism detected in the intact molecule and in proteolytic fragments. Thromb Res 1990; 58: 23342.
  • 18
    Nieuwenhuis HK, Sakariassen KS, Houdijk WP, Nievelstein PF, Sixma JJ. Deficiency of platelet membrane glycoprotein Ia associated with a decreased platelet adhesion to subendothelium: a defect in platelet spreading. Blood 1986; 68: 6925.
  • 19
    Kehrel B, Balleisen L, Kokott R, Mesters R, Stenzinger W, Clemetson KJ, Van De Loo J. Deficiency of intact thrombospondin and membrane glycoprotein Ia in platelets with defective collagen-induced aggregation and spontaneous loss of disorder. Blood 1988; 71: 10748.
  • 20
    Moroi M, Jung SM, Okuma M, Shinmyozu K. A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 1989; 84: 14405.
  • 21
    Jandrot-Perrus M, Busfield S, Lagrue AH, Xiong X, Debili N, Chickering T, Le Couedic JP, Goodearl A, Dussault B, Fraser C, Vainchenker W, Villeval JL. Cloning, characterization, and functional studies of human and mouse glycoprotein VI. a platelet-specific collagen receptor from the immunoglobulin superfamily. Blood 2000; 96: 1798807.
  • 22
    Tsuji M, Ezumi Y, Arai M, Takayama H. A novel association of Fc receptor gamma-chain with glycoprotein VI and their co-expression as a collagen receptor in human platelets. J Biol Chem 1997; 272: 2352831.
  • 23
    Lages B, Malmsten C, Weiss HJ, Samuelsson B. Impaired platelet response to thromboxane-A2 and defective calcium mobilization in a patient with a bleeding disorder. Blood 1981; 57: 54552.
  • 24
    Samama M, Lecrubier C, Conard J, Hotchen M, Breton-Gorius J, Vargaftig B, Chignard M, Lagarde M, Dechavanne M. Constitutional thrombocytopathy with subnormal response to thromboxane A2. Br J Haematol 1981; 48: 293303.
  • 25
    Wu KK, Le Breton GC, Tai HH, Chen YC. Abnormal platelet response to thromboxane A2. J Clin Invest 1981; 67: 18014.
  • 26
    Fuse I, Mito M, Hattori A, Higuchi W, Shibata A, Ushikubi F, Okuma M, Yahata K. Defective signal transduction induced by thromboxane A2 in a patient with a mild bleeding disorder: impaired phospholipase C activation despite normal phospholipase A2 activation. Blood 1993; 81: 9941000.
  • 27
    Hirata T, Kakizuka A, Ushikubi F, Fuse I, Okuma M, Narumiya S. Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994; 94: 16627.
  • 28
    Hirata T, Ushikubi F, Kakizuka A, Okuma M, Narumiya S. Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest 1996; 97: 94956.
  • 29
    Okuma M, Hirata T, Ushikubi F, Kakizuka A, Narumiya S. Molecular characterization of a dominantly inherited bleeding disorder with impaired platelet responses to thromboxane A2. Pol J Pharmacol 1996; 48: 7782.
  • 30
    Leon C, Hechler B, Vial C, Leray C, Cazenave JP, Gachet C. The P2Y1 receptor is an ADP receptor antagonized by ATP and expressed in platelets and megakaryoblastic cells. FEBS Lett 1997; 403: 2630.
  • 31
    Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden A, Julius D, Conley PB. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409: 2027.
  • 32
    Zhang FL, Luo L, Gustafson E, Lachowicz J, Smith M, Qiao X, Liu YH, Chen G, Pramanik B, Laz TM, Palmer K, Bayne M, Monsma FJ Jr. ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J Biol Chem 2001; 276: 860815.
  • 33
    Sun B, Li J, Okahara K, Kambayashi J. P2X1 purinoceptor in human platelets. Molecular cloning and functional characterization after heterologous expression. J Biol Chem 1998; 273: 115447.
  • 34
    Clifford EE, Parker K, Humphreys BD, Kertesy SB, Dubyak GR. The P2X1 receptor, an adenosine triphosphate-gated cation channel, is expressed in human platelets but not in human blood leukocytes. Blood 1998; 91: 317281.
  • 35
    Vial C, Hechler B, Leon C, Cazenave JP, Gachet C. Presence of P2X1 purinoceptors in human platelets and megakaryoblastic cell lines. Thromb Haemost 1997; 78: 15004.
  • 36
    Scase TJ, Heath MF, Allen JM, Sage SO, Evans RJ. Identification of a P2X1 purinoceptor expressed on human platelets. Biochem Biophys Res Commun 1998; 242 (3): 5258.
  • 37
    Rolf MG, Brearley CA, Mahaut-Smith MP. Platelet shape change evoked by selective activation of P2X1 purinoceptors with alpha,beta-methylene ATP. Thromb Haemost 2001; 85: 3038.
  • 38
    Cattaneo M, Marchese P, Jacobson KA, Ruggeri ZM. New insights into the role of P2X1 in platelet function. Haematologica (Suppl 1)- Platelet ADP Receptors 2002; 10: 134.
  • 39
    Oury C, Toth-Zsamboki E, Van Geet C, Thys C, Wei L, Nilius B, Vermylen J, Hoylaerts MF. A natural dominant negative P2X1 receptor due to deletion of a single amino acid residue. J Biol Chem 2000; 275: 226114.
  • 40
    Hechler B, Leon C, Vial C, Vigne P, Frelin C, Cazenave JP, Gachet C. The P2Y1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation. Blood 1998; 92: 1529.
  • 41
    Savi P, Beauverger P, Labouret C, Delfaud M, Salel V, Kaghad M, Herbert JM. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett 1998; 422: 2915.
  • 42
    Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273: 20304.
  • 43
    Jarvis GE, Humphries RG, Robertson MJ, Leff P. ADP can induce aggregation of human platelets via both P2Y (1) and P (2T) receptors. Br J Pharmacol 2000; 129: 27582.
  • 44
    Geiger J, Honig-Liedl P, Schanzenbacher P, Walter U. Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors. Eur J Pharmacol 1998; 351: 23546.
  • 45
    Fagura MS, Dainty IA, McKay GD, Kirk IP, Humphries RG, Robertson MJ, Dougall IG, Leff P. P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y (ADP)-receptors. Br J Pharmacol 1998; 124: 15764.
  • 46
    Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998; 273: 20249.
  • 47
    Jantzen HM, Gousset L, Bhaskar V, Vincent D, Tai A, Reynolds EE, Conley PB. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation. Thromb Haemost 1999; 81: 1117.
  • 48
    Leon C, Hechler B, Freund M, Eckly A, Vial C, Ohlmann P, Dierich A, LeMeur M, Cazenave JP, Gachet C. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y (1) receptor-null mice. J Clin Invest 1999; 104: 17317.
  • 49
    Fabre JE, Nguyen M, Latour A, Keifer JA, Audoly LP, Coffman TM, Koller BH. Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. Nat Med 1999; 5: 1199202.
  • 50
    Cattaneo M, Lecchi A, Lombardi R, Gachet C, Zighetti ML. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet ‘primary secretion defect’ are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol 2000; 20: E101E106.
  • 51
    Cattaneo M, Lombardi R, Zighetti ML, Gachet C, Ohlmann P, Cazenave JP, Mannucci PM. Deficiency of (33P), 2MeS–ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production. Thromb Haemost 1997: 77: 98690.
  • 52
    Cattaneo M, Canciani MT, Lecchi A, Kinlough-Rathbone RL, Packham MA, Mannucci PM, Mustard JF. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. Blood 1990; 75: 10816.
  • 53
    Trumel C, Payrastre B, Plantavid M, Hechler B, Viala C, Presek P, Martinson EA, Cazenave JP, Chap H, Gachet C. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood 1999; 94: 415665.
  • 54
    Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood 1992; 80: 278796.
  • 55
    Gachet C, Cattaneo M, Ohlmann P, Hechler B, Lecchi A, Chevalier J, Cassel D, Mannucci PM, Cazenave JP. Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors. Br J Haematol 1995; 91: 43444.
  • 56
    Conley PB, Jurek MM, Vincent D, Lecchi A, Cattaneo M. Unique mutations in the P2Y12 locus od patients with previously described defects in ADP-dependent aggregation. Blood 2001; 98: 43b.
  • 57
    Nurden P, Savi P, Heilmann E, Bihour C, Herbert JM, Maffrand JP, Nurden A. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. J Clin Invest 1995; 95: 161222.
  • 58
    Cattaneo M, Zighetti ML, Lombardi R, Martinez C, Lecchi A, Conley PB, Ware J, Ruggeri ZM. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with cangenital bleeding. Proc Natl Acad Sci USA 2003; 100: 197883.
  • 59
    Moro S, Hoffmann C, Jacobson KA. Role of the extracellular loops of G protein-coupled receptors in ligand recognition: a molecular modeling study of the human P2Y1 receptor. Biochemistry 1999; 38: 3498507.
  • 60
    Moro S, Guo D, Camaioni E, Boyer JL, Harden TK, Jacobson KA. Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites. J Med Chem 1998; 41: 145666.
  • 61
    Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999; 19: 22815.
  • 62
    Cattaneo M, Lecchi A. Patients with congenital abnormality of platelet aggregation induced by Ca (2+) ionophores may have a defect of the platelet P2Y (12) receptor for ADP. Br J Haematol 2001; 115: 4857.
  • 63
    Nieuwenhuis HK, Akkerman JW, Sixma JJ. Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood 1987; 70: 6203.
  • 64
    Rao AK. Congenital disorders of platelet secretion and signal transduction. In: Colman, RW, Hirsh, J, Marder, VJ, Clowes, AW, George, JN, eds. Hemostasis and Thrombosis. Basic Principles and Clinical Practice. Philadelphia, PA: JB Lippincot, Williams & Wilkins. 2001: 893904.
  • 65
    Holmsen H, Weiss HJ. Hereditary defect in the platelet release reaction caused by a deficiency in the storage pool of platelet adenine nucleotides. Br J Haematol 1970; 19: 6439.
  • 66
    Holmsen H, Weiss HJ. Further evidence for a deficient storage pool of adenine nucleotides in platelets from some patients with thrombocytopathia –‘storage pool disease’. Blood 1972; 39: 197209.
  • 67
    Weiss HJ, Witte LD, Kaplan KL, Lages BA, Chernoff A, Nossel HL, Goodman DS, Baumgartner HR. Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in alpha-granules, platelet factor 4, beta-thromboglobulin, and platelet-derived growth factor. Blood 1979; 54: 1296319.
  • 68
    Lages B, Scrutton MC, Holmsen H, Day HJ, Weiss HJ. Metal ion contents of gel-filtered platelets from patients with storage pool disease. Blood 1975; 46: 11930.
  • 69
    Akkerman JW, Nieuwenhuis HK, Mommersteeg-Leautaud ME, Gorter G, Sixma JJ. ATP-ADP compartmentation in storage pool deficient platelets: correlation between granule-bound ADP and the bleeding time. Br J Haematol 1983; 55: 13543.
  • 70
    Cattaneo M, Lecchi A, Agati B, Lombardi R, Zighetti ML. Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion. Thromb Res 1999; 96: 2137.
  • 71
    Lages B, Weiss HJ. Biphasic aggregation responses to ADP and epinephrine in some storage pool deficient platelets: relationship to the role of endogenous ADP in platelet aggregation and secretion. Thromb Haemost 1980; 43: 14753.
  • 72
    Hazelwood S, Shotelersuk V, Wildenberg SC, Chen D, Iwata F, Kaiser-Kupfer MI, White JG, King RA, Gahl WA. Evidence for locus heterogeneity in Puerto Ricans with Hermansky–Pudlak syndrome. Am J Hum Genet 1997; 61: 108894.
  • 73
    Oh J, Ho L, Ala-Mello S, Amato D, Armstrong L, Bellucci S, Carakushansky G, Ellis JP, Fong CT, Green JS, Heon E, Legius E, Levin AV, Nieuwenhuis HK, Pinckers A, Tamura N, Whiteford ML, Yamasaki H, Spritz RA. Mutation analysis of patients with Hermansky–Pudlak syndrome: a frameshift hot spot in the HPS gene and apparent locus heterogeneity. Am J Hum Genet 1998; 62: 5938.
  • 74
    Dell'Angelica EC, Shotelersuk V, Aguilar RC, Gahl WA, Bonifacino JS. Altered trafficking of lysosomal proteins in Hermansky–Pudlak syndrome due to mutations in the beta 3A subunit of the AP-3 adaptor. Mol Cell 1999; 3: 1121.
  • 75
    Introne W, Boissy RE, Gahl WA. Clinical, molecular, and cell biological aspects of Chediak–Higashi syndrome. Mol Genet Metab 1999; 68: 283303.
  • 76
    Day HJ, Holmsen H. Platelet adenine nucleotide ‘storage pool deficiency’ in thrombocytopenic absent radii syndrome. JAMA 1972; 221: 10534.
  • 77
    Grottum KA, Hovig T, Holmsen H, Abrahamsen AF, Jeremic M, Seip M. Wiskott–Aldrich syndrome: qualitative platelet defects and short platelet survival. Br J Haematol 1969; 17: 37388.
  • 78
    Raccuglia G. Gray platelet syndrome. A variety of qualitative platelet disorder. Am J Med 1971; 51: 81828.
  • 79
    Jantunen E, Hanninen A, Naukkarinen A, Vornanen M, Lahtinen R. Gray platelet syndrome with splenomegaly and signs of extramedullary hematopoiesis: a case report with review of the literature. Am J Hematol 1994; 46: 21824.
  • 80
    Caen JP, Deschamps JF, Bodevin E, Bryckaert MC, Dupuy E, Wasteson A. Megakaryocytes and myelofibrosis in gray platelet syndrome. Nouv Rev Fr Hematol 1987; 29: 10914.
  • 81
    Tracy PB, Giles AR, Mann KG, Eide LL, Hoogendoorn H, Rivard GE. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet Factor V deficiency. J Clin Invest 1984; 74: 12218.
  • 82
    Hayward CP, Rivard GE, Kane WH, Drouin J, Zheng S, Moore JC, Kelton JG. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. Blood 1996; 87: 496778.
  • 83
    Breton-Gorius J, Favier R, Guichard J, Cherif D, Berger R, Debili N, Vainchenker W, Douay L. A new congenital dysmegakaryopoietic thrombocytopenia (Paris-Trousseau) associated with giant platelet alpha-granules and chromosome 11 deletion at 11q23. Blood 1995; 85: 180514.
  • 84
    Hart A, Melet F, Grossfeld P, Chien K, Jones C, Tunnacliffe A, Favier R, Bernstein A. Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity 2000; 13: 16777.
  • 85
    Weiss HJ, Lages B, Vicic W, Tsung LY, White JG. Heterogeneous abnormalities of platelet dense granule ultrastructure in 20 patients with congenital storage pool deficiency. Br J Haematol 1993; 83: 28295.
  • 86
    Weiss HJ, Witte LD, Kaplan KL, Lages BA, Chernoff A, Nossel HL, Goodman DS, Baumgartner HR. Heterogeneity in storage pool deficiency: studies on granule-bound substances in 18 patients including variants deficient in alpha-granules, platelet factor 4, beta-thromboglobulin, and platelet-derived growth factor. Blood 1979; 54: 1296319.
  • 87
    Gabbeta J, Yang X, Kowalska MA, Sun L, Dhanasekaran N, Rao AK. Platelet signal transduction defect with Galpha subunit dysfunction and diminished Galphaq in a patient with abnormal platelet responses. Proc Natl Acad Sci USA 1997; 94: 87505.
  • 88
    Lee SB, Rao AK, Lee KH, Yang X, Bae YS, Rhee SG. Decreased expression of phospholipase C-beta 2 isozyme in human platelets with impaired function. Blood 1996; 88: 168491.
  • 89
    Gabbeta J, Yang X, Sun L, McLane MA, Niewiarowski S, Rao AK. Abnormal inside-out signal transduction-dependent activation of glycoprotein IIb-IIIa in a patient with impaired pleckstrin phosphorylation. Blood 1996; 87: 136876.
  • 90
    Freson K, Hoylaerts MF, Jaeken J, Eyssen M, Arnout J, Vermylen J, Van Geet C. Genetic variation of the extra-large stimulatory G protein alpha- subunit leads to Gs hyperfunction in platelets and is a risk factor for bleeding. Thromb Haemost 2001; 86: 7338.
  • 91
    Weiss HJ. Scott syndrome: a disorder of platelet coagulant activity. Semin Hematol 1994; 31: 3129.
  • 92
    Solum NO. Procoagulant expression in platelets and defects leading to clinical disorders. Arterioscler Thromb Vasc Biol 1999; 19: 28416.
  • 93
    Weiss HJ. Congenital disorders of platelet function. Semin Hematol 1980; 17: 22841.
  • 94
    Rao AK, Gabbeta J. Congenital disorders of platelet signal transduction. Arterioscler Thromb Vasc Biol 2000; 20: 2859.
  • 95
    Milton JG, Frojmovic MM, Tang SS, White JG. Spontaneous platelet aggregation in a hereditary giant platelet syndrome (MPS). Am J Pathol 1984; 114: 33645.